Early response as a predictor of long-term clinical response in DMARD-naive patients with severe, active and progressive rheumatoid arthritis treated with certolizumab pegol plus optimized MTX versus optimized MTX alone

X. Mariette, C. Bingham, G. Burmester, V. Bykerk, P. Emery, D. E. Furst, D. Van Der Heijde, R. Van Vollenhoven, B. Vanlunen, C. Arendt, M. Weinblatt

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Early response as a predictor of long-term clinical response in DMARD-naive patients with severe, active and progressive rheumatoid arthritis treated with certolizumab pegol plus optimized MTX versus optimized MTX alone'. Together they form a unique fingerprint.